BioCentury | Sep 24, 2012
Strategy

Where innovation lives

...with product discovery and development out there," said Stoffels, who was CEO of virology company Tibotec-Virco...
BioCentury | Oct 11, 2010
Strategy

Platform Trifecta

...platform-based acquisitions, one of antibody company Centocor Inc. in 1999 and another of antiviral company Tibotec-Virco...
BioCentury | Jun 30, 2008
Company News

Movetis management update

...S.A. ; and Dirk Van Broekhoven as general counsel, formerly head of law group of Tibotec-Virco...
BioCentury | Jun 27, 2007
Financial News

Drakeman, Pauwels join Advent

Advent hired Donald Drakeman and Rudi Pauwels as venture partners on its life sciences team. Drakeman was founder and former president and CEO of Medarex (MEDX). Pauwels, founder and former CEO and CSO of Tibotec...
BioCentury | Jan 13, 2003
Finance

Europe's dilemma

...and CAT. Other deals include $100 million in a private placement for infectious disease play Tibotec-Virco...
BioCentury | Oct 7, 2002
Company News

Newron Pharmaceuticals SpA management update

...Business: Neurological Hired: Christophe Bourrilly as VP of finance, formerly director of corporate finance at Tibotec-Virco...
BioCentury | Sep 9, 2002
Company News

XTL management update

...Graham as CMO, formerly VP of clinical research and medical affairs at Johnson & Johnson’s Tibotec-Virco...
BioCentury | Apr 22, 2002
Company News

Tibotec-Virco NV, J&J deal

...announced acquisition of Tibotec-Virco for $320 million in cash and debt (see BioCentury, March 25). Tibotec-Virco...
BioCentury | Apr 1, 2002
Finance

M&A as a driver

...Schering AG take out Collateral Therapeutics on a big premium plus Johnson & Johnson acquire Tibotec-Virco...
BioCentury | Mar 25, 2002
Strategy

Schering regenerates with Collateral

...may be a different story." JNJ catches anti-viral fever Johnson & Johnson 's acquisition of Tibotec-Virco...
...Belgian biotech will get the capital necessary to continue its clinical and preclinical development programs. Tibotec-Virco's...
...the second quarter, while its TMC-114 protease inhibitor is in Phase IIa trials. In addition, Tibotec-Virco...
Items per page:
1 - 10 of 38
BioCentury | Sep 24, 2012
Strategy

Where innovation lives

...with product discovery and development out there," said Stoffels, who was CEO of virology company Tibotec-Virco...
BioCentury | Oct 11, 2010
Strategy

Platform Trifecta

...platform-based acquisitions, one of antibody company Centocor Inc. in 1999 and another of antiviral company Tibotec-Virco...
BioCentury | Jun 30, 2008
Company News

Movetis management update

...S.A. ; and Dirk Van Broekhoven as general counsel, formerly head of law group of Tibotec-Virco...
BioCentury | Jun 27, 2007
Financial News

Drakeman, Pauwels join Advent

Advent hired Donald Drakeman and Rudi Pauwels as venture partners on its life sciences team. Drakeman was founder and former president and CEO of Medarex (MEDX). Pauwels, founder and former CEO and CSO of Tibotec...
BioCentury | Jan 13, 2003
Finance

Europe's dilemma

...and CAT. Other deals include $100 million in a private placement for infectious disease play Tibotec-Virco...
BioCentury | Oct 7, 2002
Company News

Newron Pharmaceuticals SpA management update

...Business: Neurological Hired: Christophe Bourrilly as VP of finance, formerly director of corporate finance at Tibotec-Virco...
BioCentury | Sep 9, 2002
Company News

XTL management update

...Graham as CMO, formerly VP of clinical research and medical affairs at Johnson & Johnson’s Tibotec-Virco...
BioCentury | Apr 22, 2002
Company News

Tibotec-Virco NV, J&J deal

...announced acquisition of Tibotec-Virco for $320 million in cash and debt (see BioCentury, March 25). Tibotec-Virco...
BioCentury | Apr 1, 2002
Finance

M&A as a driver

...Schering AG take out Collateral Therapeutics on a big premium plus Johnson & Johnson acquire Tibotec-Virco...
BioCentury | Mar 25, 2002
Strategy

Schering regenerates with Collateral

...may be a different story." JNJ catches anti-viral fever Johnson & Johnson 's acquisition of Tibotec-Virco...
...Belgian biotech will get the capital necessary to continue its clinical and preclinical development programs. Tibotec-Virco's...
...the second quarter, while its TMC-114 protease inhibitor is in Phase IIa trials. In addition, Tibotec-Virco...
Items per page:
1 - 10 of 38